Happy New Year!
The Business of Biotech podcast took its annual sojourn to San Francisco for the JP Morgan Healthcare Conference, where we recorded a series of episodes that we'll be dropping over the next several weeks. Anyone who's been to the conference knows the premium we sojourners pay for some temporary real estate there. Makes me wonder how many clinical trials we could fund with the money spent on living and meeting space that week. We're incredibly grateful to our friends at Alston & Bird, who partnered up with us this year and carved out a piece of their offices a few blocks from Union Square for us to record. If you need some world-class biotech law chops, Alston & Bird has you covered.
Stay tuned for our JPM series, starring the builders of XOMA Royalty, Landmark Bio, QurAlis, Capsida, 3T Bio, and more. In the meantime, here are some hand-picked favorites from the past month at Life Science Connect and the Business of Biotech.
Matt Pillar, Business of Biotech host and chief editor, Bioprocess Online |
|
| | Biotech Beat | January 21, 2025 |
|
| ![]() | | by JIM STREETER | It's easy to find opinions on AI in pharma from the growing field of solution providers cropping up to serve the space. More valuable are "inside" perceptions from people like Jim Streeter, who led clinical data services at Pfizer and, later, global life sciences customer success efforts at Oracle. He offers his pragmatic take in this exclusive for Life Science Leader. | READ NOW → |
|
![]() | | Speaking of inside scoop, Bioprocess Online & Cell & Gene's Tyler Menichiello sat down for an exclusive interview with Ossium Health's Kevin Caldwell, FibroBiologics' Hamid Khoja, Ph.D., and Triumvira Immunologics' Rob Williamson for their expectations of the cell and gene therapy space in the coming year. Here it is in its entirety on Cell & Gene, where you'll also find shorts of the interview if you're pressed for time. | READ NOW → |
|
| ![]() | | by ANNA ROSE WELCH | Who better to reflect on a year of advances in RNA therapeutics than the woman who leads Advancing RNA? Our own Anna Rose Welch had so much to say about the past year in the space, she wrote a two-parter on the topic (part 2 is here). If you've listened to Anna Rose on the Business of Biotech, you know her astute observations aren't to be missed. | READ NOW → |
|
![]() | | by LOUIS GARGUILO | In keeping with our retrospective and forward-looking theme, Outsourced Pharma's Louis Garguilo put together a string of editorial pieces reflecting on a topsy-turvy year in the outsourced manufacturing space and what we can expect in 2025. From big M&A deals (Novo/Catalent) to big policy disruptions (BIOSECURE Act), he's been on it all year. Here's his latest, complete with predictions from Pharmatech Associates' Bikash Chatterjee. | READ NOW → |
|
| | "I just saw an opportunity to translate what I thought was a fascinating bit in science and to push it along outside of the research/curiosity domain into the let's put it on a path to making medicines domain." | ― Tal Zaks, M.D., Ph.D., Chairman & CEO, Exsilio Therapeutics, Episode 235 |
|
| "In the pure academic setting, there's not necessarily a roadmap of how to commercialize and go after therapeutic development. It's always been known as this valley of death between academics and industry." | ― Jeff Coller, Ph.D., Bloomberg Distinguished Professor of RNA Biology and Therapeutics, Johns Hopkins University, Episode 236 |
|
| "I found that life sciences industry is hard to penetrate for someone who doesn't have PhD in biology and doesn't have all the credentials in academia or industry. Like, who am I?" | ― Andrey Doronichev, Founder, BIOPTIC, Episode 237 |
|
| | | ![]() | Created exclusively for the leaders of new and emerging biopharma firms, the Business of Biotech podcast tackles organizational, funding, HR, regulatory, production and CMC considerations with insight from peer founders who have taken biologic therapies from an idea to clinical success. Check out our episode archive. | |
|
|
|
Ensure our newsletter reaches your inbox by following these whitelist instructions.
This newsletter is being sent to {{lead.Email Address}}. To cancel your subscription to the newsletter, please opt out. | © Copyright 2024 Vertmarkets, Inc. 5340 Fryling Rd Suite 100, Erie, PA 16510.
All rights reserved. All product names contained herein are the trademarks of their respective holders. |
|
|
|
|
